Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
WARRINGTON, Pa. , April 24, 2023 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the closing of its previously announced underwritten
Article Date
April 24, 2023
This article is featured on another website.
Go to article
June 1, 2026
Chime Biologics and Daewoong Pharmaceutical Enter Strategic Partnership to Advance Dupilumab Biosimilar Development and Commercialization in Global Markets
June 1, 2026
Chime Biologics and Daewoong Pharmaceutical Enter Strategic Partnership to Advance Dupilumab Biosimilar Development and Commercialization in Global Markets
April 28, 2026
Clinical Research Consulting vs. FSP in Biotech and Pharma: Knowing When an FSP Is the Right Fit
Clinical Research Consulting vs. FSP: Choosing the Right Model for Biotech and Pharma Companies Biotech…
April 28, 2026
Clinical Research Consulting vs. FSP in Biotech and Pharma: Knowing When an FSP Is the Right Fit
Clinical Research Consulting vs. FSP: Choosing the Right Model for Biotech and Pharma Companies Biotech…